Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol

M. R. Liebowitz, J. M. Gorman, A. J. Fyer, R. Campeas, A. P. Levin, D. Sandberg, E. Hollander, L. Papp, D. Goetz

Research output: Contribution to journalArticle

106 Scopus citations

Abstract

Forty-one patients meeting DSM-III criteria for social phobia completed a randomized comparative trial of the monoamine oxidase inhibitor phenelzine, the cardioselective β-adrenergic blocker atenolol, and placebo. No significant differences were seen after 4 weeks of treatment in this preliminary trial. At the end of 8 weeks, however, phenelzine demonstrated greater efficacy than atenolol or placebo on dimensional ratings of overall severity of social phobia. No atenolol-placebo differences were observed. The authors shall present maintenance and discontinuation findings in a final report. Phenelzine may act in patients with social phobia by directly reducing interpersonal hypersensitivity.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalJournal of Clinical Psychiatry
Volume49
Issue number7
StatePublished - Jan 1 1988
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol'. Together they form a unique fingerprint.

  • Cite this

    Liebowitz, M. R., Gorman, J. M., Fyer, A. J., Campeas, R., Levin, A. P., Sandberg, D., Hollander, E., Papp, L., & Goetz, D. (1988). Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry, 49(7), 252-257.